ReNeuron Group PLC

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)46.35
  • Today's Change-31.15 / -40.19%
  • Shares traded3.65m
  • 1 Year change-65.41%
  • Beta1.7687
Data delayed at least 20 minutes, as of Jan 18 2022 12:41 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based cell-based therapeutics company. The Company develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate.

  • Revenue in GBP (TTM)274.00k
  • Net income in GBP-9.49m
  • Incorporated2005
  • Employees43.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttp://www.reneuron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
NAHL Group PLC40.15m577.00k22.51m255.0038.970.39563.780.56080.01250.01080.86771.230.4004--1.53157,447.104.107.685.239.5947.4950.6410.2314.93--11.600.263583.12-20.34-4.2292.40--34.65--
Christie Group plc51.97m629.00k27.06m1.11k43.24--10.450.52070.02360.02361.97-0.24761.34--11.8146,943.991.633.433.097.58----1.211.701.17-1.981.7043.01-45.90-7.91-226.14---1.11--
DSW Capital PLC2.69m1.38m27.07m9.0019.589.9718.6810.070.06430.06430.12570.1264------298,777.80------------51.17------0.3353--39.37--59.44------
Skillcast Group PLC7.43m866.13k31.76m81.0036.678.5829.414.280.00970.00970.0830.0414------110,867.50--------68.41--11.66----61.950.0509--7.86---43.47------
Silver Bullet Data Services Group Ltd-100.00bn-100.00bn32.21m62.00--2.54----------0.9465----------------------------0.0151--80.75--13.03------
Empresaria Group plc250.20m-900.00k40.88m1.76k--1.125.520.1634-0.0182-0.01824.930.73311.96--5.94141,836.70-0.62651.86-1.594.5521.6620.46-0.31970.7459--8.570.524739.34-28.356.49-287.50---4.902.13
ReNeuron Group Plc274.00k-9.49m44.22m43.00--3.12--161.40-0.1854-0.18540.00540.24860.0149--0.40536,372.09-51.51-34.68-86.63-40.80-----3,463.14-1,088.16---68.980.0429---95.7654.710.5696---38.88--
Ebiquity plc53.79m-3.55m44.76m550.00--1.6030.180.8322-0.0429-0.04030.65140.35690.6686--2.2697,798.18-4.22-1.96-5.89-2.6153.4852.13-6.32-3.15--3.080.4863---16.54--48.31------
Gattaca PLC415.73m1.79m44.88m483.0025.,716.401.62-2.223.49-4.2410.1110.760.4303-0.5376--2.400.2699---22.25-7.61146.08-29.0018.76-42.07
Deepverge PLC6.80m-4.23m55.40m9.00--2.19--8.15-0.0256-0.02560.04140.11760.33713.774.12---20.99-43.87-24.27-66.6643.7045.96-62.27-222.572.36-8.070.1056--444.71306.88-19.68--10.16--
System1 Group PLC25.06m2.69m56.06m146.0020.826.6220.462.240.2090.2091.970.6571.42--4.23187,014.9015.21--22.93--83.65--10.75----23.200.368---10.35--831.60------
Carillion plc4.41bn-1.07bn56.33m31.63k------0.0128-2.49-2.499.74-1.011.1560.953.36139,493.50-27.663.40-60.046.407.939.31-24.103.490.71760.72031.7361.0011.241.14-6.48-1.6024.241.77
Frontier IP Group Plc12.67m9.57m57.76m16.006.331.506.034.560.16580.16580.22010.69850.3901--17.78791,750.0029.4619.8329.6520.01----75.5165.15----0.000.0098.6544.23128.6353.2743.10--
Data as of Jan 18 2022. Currency figures normalised to ReNeuron Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

40.47%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 01 Nov 20213.82m6.69%
Jarvis Investment Management Ltd.as of 01 Nov 20213.45m6.04%
Octopus Investments Ltd.as of 04 Jun 20213.35m5.87%
Schroder Investment Management Ltd.as of 12 Mar 20212.84m4.97%
Woodford Investment Management Ltd.as of 01 Nov 20212.64m4.62%
Hargreaves Lansdown Asset Management Ltd.as of 01 Nov 20212.26m3.96%
Nomura International Plc (Market-Maker)as of 01 Nov 20211.49m2.62%
Walker Crips Investment Management Ltd.as of 01 Nov 20211.39m2.43%
KW Investment Management Ltd.as of 01 Nov 20211.15m2.01%
Smith & Williamson Investment Management LLPas of 01 Nov 2021724.00k1.27%
More ▼
Data from 30 Sep 2021 - 03 Jan 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.